Trial Profile
A 12-Week Study to Assess the Efficacy and Safety of AF 219 in Subjects With Refractory Chronic Cough
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs Gefapixant (Primary)
- Indications Cough
- Focus Therapeutic Use
- Sponsors Afferent Pharmaceuticals
- 20 May 2020 Results assessing difference in cough frequency and patient-assessment of cough severity, presented at the 116th International Conference of the American Thoracic Society.
- 16 Mar 2020 Results evaluating comorbid conditions and secondary diagnoses associated with cough using two phase II trials (NCT02349425 and NCT02612610) presented at the 2020 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 25 Feb 2019 Results of post-hoc analysis assessing proportion of responders in terms of cough trigger presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.